FUNDAMENTALS · Fundamentals · US Healthcare

Cumberland Pharmaceuticals (CPIX) Fundamentals 2026 — Revenue Analysis | SniperIQ

Cumberland Pharmaceuticals (CPIX) is a US-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of

08M, trading at $7.24 on the NASDAQ. This SniperIQ fundamentals page covers Cumberland Pharmaceuticals's valuation, profitability (net margin -17.2%), revenue ($45M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
08M
Net Margin-17.2%
Revenue (FY25)$45M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Cumberland Pharmaceuticals's market cap?

Cumberland Pharmaceuticals (CPIX) has a market capitalization of approximately

08M, trading at $7.24 on the NASDAQ. Market cap moves with the live share price.

What is Cumberland Pharmaceuticals's P/E ratio?

Cumberland Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 5.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals runs a net profit margin of -17.2%, a gross margin of 82.9%, and an operating margin of -17.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Cumberland Pharmaceuticals generate?

Cumberland Pharmaceuticals reported revenue of $45M for fiscal year 2025, with net income of -

M and earnings per share (EPS) of -0.19. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Cumberland Pharmaceuticals pay a dividend?

Cumberland Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Cumberland Pharmaceuticals financially healthy?

Cumberland Pharmaceuticals carries a debt-to-equity ratio of 0.47x and a current ratio of 0.95x, with a market beta of 0.10. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Cumberland Pharmaceuticals a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Cumberland Pharmaceuticals (CPIX) the key facts are: market cap

08M, revenue $45M, 52-week range 1.85-8.09. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Cumberland Pharmaceuticals's full fundamentals live

Get Cumberland Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Al-Modawat Specialized Medical (9594) fundamentals · Humacyte (HUMA) fundamentals · Corbus Pharmaceuticals Holdings (CRBP) fundamentals · biote (BTMD) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons